Details about  YU-GI-OH CARD: TAILOR OF THE FICKLE - DB1-EN026 Individual Yu-Gi-Oh! Cards


  1. Home
  2. Details about  YU-GI-OH CARD: TAILOR OF THE FICKLE - DB1-EN026
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Details about   YU-GI-OH CARD: TAILOR OF THE FICKLE - DB1-EN026
Condition: New: A brand-new, unused, unopened, undamaged item (including handmade items). See the seller's Game: Yu-Gi-Oh! TCG
Card Size: Japanese Manufacturer: Konami
Country/Region of Manufacture: Belgium Set: Dark Beginning 1
Custom Bundle: No Rarity: Common
Finish: Regular Card Condition: Mint
MPN:

Does not apply

Language: English
Material: Card Stock Features: Unlimited
Vintage: No Autographed: No
Brand:

Yu-Gi-Oh! Trading Card Game

Age Level: 6+


published on tue nov 09 2021

Details about  YU-GI-OH CARD: TAILOR OF THE FICKLE - DB1-EN026 Individual Yu-Gi-Oh! Cards

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Details about  YU-GI-OH CARD: TAILOR OF THE FICKLE - DB1-EN026 Individual Yu-Gi-Oh! Cards

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS